Laparoscopic Versus Open Retroperitoneal Lymph Node Dissection: a Cost Analysis
- 1 November 2002
- journal article
- Published by Wolters Kluwer Health in Journal of Urology
- Vol. 168 (5) , 1945-1949
- https://doi.org/10.1016/s0022-5347(05)64269-3
Abstract
Laparoscopic retroperitoneal lymph node dissection is significantly less morbid than open retroperitoneal lymph node dissection but it is generally more costly due to longer operative time and disposable equipment. In response to budgetary pressure at our large county hospital we identified the cost components of laparoscopic retroperitoneal lymph node dissection that could be targeted to decrease procedure costs before expanding our laparoscopic retroperitoneal lymph node dissection program. A comprehensive literature review of open and laparoscopic retroperitoneal lymph node dissection was performed and certain parameters were abstracted, including operative time and equipment, hospital stay, perioperative complications and surgical success rates. Using these data the projected overall cost and individual cost centers at our institution were compared for open and laparoscopic retroperitoneal lymph node dissection. Decision tree analysis models were devised to estimate the cost of each treatment using commercially available software. We performed 1 and 2-way sensitivity analysis to evaluate the effect of individual treatment variables on overall cost. Base case analysis involved a young man with clinical stage I nonseminomatous testicular cancer who was a candidate for retroperitoneal lymph node dissection. Based on a review of the costs at our institution open retroperitoneal lymph node dissection was a less costly procedure at $7,162 versus $7,804 for the laparoscopic approach. The slight cost superiority of the open approach was due to significantly lower costs associated with operating room time and equipment. On the other hand, the laparoscopic procedure showed a cost advantage for hospital stay. On 1-way sensitivity analysis laparoscopic dissection was less costly when operative time was less than 3.6 hours, hospitalization was less than 2.2 days or laparoscopic equipment costs were less than $768. On 2-way sensitivity analysis the laparoscopic approach was cost advantageous when performed in less than 5 hours or when the patient was discharged home within 2 days postoperatively. The primary cost variables for surgical treatment for testicular cancer include operative time, hospital stay and equipment cost. According to published data and decision tree analysis open retroperitoneal lymph node dissection is slightly less costly (less than $650) than laparoscopic retroperitoneal lymph node dissection for the surgical treatment of clinical stage I nonseminomatous testicular cancer at our institution. Our model identifies several measures that can be applied at any institution to render laparoscopic retroperitoneal lymph node dissection economically superior to the open approach.Keywords
This publication has 16 references indexed in Scilit:
- RANDOMIZED CONTROLLED TRIAL OF HAND-ASSISTED LAPAROSCOPIC VERSUS OPEN SURGICAL LIVE DONOR NEPHRECTOMY1Transplantation, 2001
- LAPAROSCOPIC VERSUS OPEN RADICAL NEPHRECTOMY: A 9-YEAR EXPERIENCEJournal of Urology, 2000
- LAPAROSCOPIC RETROPERITONEAL LYMPH NODE DISSECTION FOR CLINICAL STAGE I NONSEMINOMATOUS TESTICULAR CARCINOMA: LONG-TERM OUTCOMEJournal of Urology, 2000
- Long–Term Experience with Laparoscopic Retroperitoneal Lymph Node Dissection in the Management of Low–Stage Testis CancerEuropean Urology, 2000
- Laparoscopic retroperitoneal lymph node dissection for clinical stage I nonseminomatous germ cell testicular tumorsUrology, 1999
- RETROPERITONEAL LAPAROSCOPIC VERSUS OPEN RADICAL NEPHRECTOMYJournal of Urology, 1999
- Retroperitoneal Lymphadenectomy for Clinical Stage I Nonseminomatous Testicular Tumor: Laparoscopy Versus Open Surgery and Impact of Learning CurveJournal of Urology, 1996
- Primary Retroperitoneal Lymph Node Dissection in Clinical Stage A Non‐seminomatous Germ Cell Testis Cancer Review of the Indiana University Experience 1965–1989British Journal of Urology, 1993
- Is adjuvant chemotherapy necessary for patients with stage B1 testicular cancer?Journal of Clinical Oncology, 1991
- Clinical Stage 1 Testicular Cancer: The Role of Modified Retroperitoneal LymphadenectomyJournal of Urology, 1990